Alpa Laboratories Limited has announced a key management change with the resignation of its Company Secretary and Compliance Officer. The pharmaceutical company, based in Indore, Madhya Pradesh, has informed stock exchanges about this corporate development in accordance with regulatory requirements.

Key Management Change Details

Ms. Srashiti Chopra has tendered her resignation from the position of Company Secretary and Compliance Officer of Alpa Laboratories Limited. The resignation letter was submitted on February 25, 2026, with the cessation taking effect from the close of business hours on March 25, 2026.

Regulatory Compliance and Notification

The company has fulfilled its disclosure obligations under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Formal notifications were sent to both major stock exchanges where the company's shares are listed.

The regulatory filings were addressed to:

• National Stock Exchange of India Limited (Scrip Code: ALPA)
• Bombay Stock Exchange Limited (Scrip Code: 532878)

Transition and Professional Acknowledgment

In her resignation letter, Ms. Chopra expressed appreciation for the opportunities and professional experience gained during her tenure with the organization. She acknowledged the guidance, support, and trust extended to her throughout her association with the company.

Key aspects of the transition include:

• Commitment to ensuring smooth handover of responsibilities
• Completion of all pending assignments during the notice period
• Close collaboration with the team to maintain work continuity
• Full dedication to duties until the effective resignation date

Corporate Governance Impact

The resignation represents a significant change in the company's compliance and secretarial functions. As Company Secretary and Compliance Officer, Ms. Chopra was responsible for ensuring adherence to regulatory requirements and maintaining corporate governance standards. The company will need to identify and appoint a suitable replacement to fill this critical role.

Director Mahendra Singh Chawla signed the official communication to the stock exchanges, confirming the company's commitment to transparent disclosure of material changes in key management personnel.

Alpa Laboratories Limited announced its unaudited financial results for the quarter ended December 31, 2025, showing mixed performance with revenue growth but declining profitability compared to the previous year.

Financial Performance Overview

The pharmaceutical company reported revenue from operations of Rs 2,967.12 lacs for Q3FY26, representing a growth of 13.5% from Rs 2,615.02 lacs in the corresponding quarter of FY25. However, net profit declined significantly to Rs 187.48 lacs from Rs 889.30 lacs in Q3FY25, marking a decrease of 78.9%.

Nine-Month Performance

For the nine months ended December 31, 2025, Alpa Laboratories achieved revenue from operations of Rs 7,441.40 lacs compared to Rs 7,253.26 lacs in the corresponding period of the previous year, showing growth of 2.6%. Net profit for the nine-month period stood at Rs 1,375.20 lacs versus Rs 2,166.42 lacs in the previous year.

Cost Structure Analysis

The company's cost structure showed significant changes during the quarter. Cost of materials consumed increased substantially to Rs 1,816.08 lacs in Q3FY26 from Rs 1,273.98 lacs in Q3FY25. Employee benefit expenses rose to Rs 371.79 lacs from Rs 336.11 lacs year-over-year. Other income declined sharply to Rs 26.05 lacs from Rs 880.17 lacs in the previous year quarter.

Consolidated Results

On a consolidated basis, which includes subsidiary Norfolk Mercantile Private Limited, the company reported revenue from operations of Rs 2,904.58 lacs for Q3FY26. Consolidated net profit was Rs 190.29 lacs compared to Rs 890.18 lacs in Q3FY25. The subsidiary contributed minimal revenue but reported a net loss of Rs 3.42 lacs for both the quarter and nine-month periods.

Corporate Information

Alpa Laboratories Limited operates in the single segment of drugs and chemicals. The company maintains its registered office at 33/2, A.B. Road, Pigdamber-453446, District Indore, Madhya Pradesh. The Board of Directors approved these unaudited standalone and consolidated financial results in a meeting held on February 11, 2026, with limited review reports from statutory auditors C.H. Padliya & Co.